# Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

> **NCT05981001** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 170 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **PROCEDURE:** Surgery for harvesting tumor-draining lymph nodes
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Tumor-draining lymph node-derived lymphocyte (LNL)
- **BIOLOGICAL:** Interleukin-2
- **BIOLOGICAL:** Camrelizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05981001
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2032-04-30
- **Final completion:** 2035-04-30
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05981001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05981001, "Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05981001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*